James Calder, Co-Chair of firm’s Antitrust Practice, was quoted in an article in Dow Jones International News on the potential buyout of Alcon by Novartis. The Swiss drug maker already owns a quarter of Alcon and has the option to buy Nestle’s remaining stake starting January 1. Mr. Calder says that competition between the drug maker and Alcon, which concentrates on eye products, would not be a concern. “Overall there is not a great deal of overlap, the businesses are complementary. There are no obvious issues here which are big obstacles,” he says. (“Focus Shifts to Novartis’ Plans for Alcon Minorities,” December 10, 2009)